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Background: Topical diclofenac, a nonsteroidal anti-inflammatory drug, has proven 
efficacy and safety in the management of osteoarthritis pain. 
Objective: We investigated penetration of topical diclofenac into knee synovial tissue 
and fluid (primary objective) and evaluated relative exposure in the knee versus plasma 
(secondary objective). 
Design: In this phase 1, double-blind, multicenter study, patients scheduled for 
arthroplasty for end-stage knee osteoarthritis were randomly assigned 2:1 to 4 g 
diclofenac diethylamine 2.32% w/w gel (92.8 mg diclofenac diethylamine, equivalent to 
74.4 mg diclofenac, per application) or placebo gel, applied to the affected knee by a 
trained nurse/designee every 12 hours for 7 days before surgery. Diclofenac 
concentrations were measured in synovial tissue, synovial fluid, and plasma from 
samples obtained during surgery ≥12 hours after last application. Treatment-emergent 
adverse events (TEAEs) were evaluated. 
Results: Evaluable synovial tissue or fluid samples were obtained from 45 (diclofenac 
n=29; placebo n=16) of 47 patients. All diclofenac-treated participants had measurable 
diclofenac concentrations in synovial tissue (geometric mean 1.57 [95% CI, 1.12, 2.20] 
ng/g) and fluid (geometric mean 2.27 [95% CI, 1.87, 2.76] ng/mL) ≥12 hours after the 
last dose. Geometric mean (95% CI) ratio of diclofenac in synovial tissue:plasma was 
0.32 (0.23, 0.45) and in synovial fluid:plasma was 0.46 (0.40, 0.54). TEAE rates were 
similar for diclofenac (55.2%) and placebo (58.8%); none were treatment related. 
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Conclusions: Topical diclofenac diethylamine 2.32% w/w gel penetrated into the 
osteoarthritic knee after repeated application, and remained detectable in synovial 
tissue and fluid at the end of the final 12-hour dosing cycle. 
 
Keywords: osteoarthritis, diclofenac, nonsteroidal anti-inflammatory agents, 





Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are a generally well-tolerated 
and effective treatment for pain related to osteoarthritis (OA).1-3 Clinical guidelines 
support a role for topical NSAIDs for symptom management in patients with knee and/or 
hand OA.4-9 Topical diclofenac, one of the most-studied topical NSAIDs, has a well-
established efficacy and safety profile.1-3 In head-to-head trials, efficacy was at least 
equivalent to that of some oral NSAIDs.10-12 Adverse events (AEs) of topical diclofenac 
are primarily local skin and subcutaneous tissue disorders,13 with minimal systemic AEs 
due to low systemic concentrations (3%‒5% of total systemic absorption for oral 
diclofenac).14 
 Topical NSAIDs deliver active drug directly to the site of pain and inflammation, 
avoid first-pass metabolism, and minimize systemic AEs.15 Therapeutic efficacy is 
presumably dependent on skin penetration and the ability to deliver 
pharmacodynamically active concentrations to the underlying site of pain and 
inflammation in the affected joint.15,16 However, the disposition of topical diclofenac is 
not fully characterized, and no such studies have been performed using topical 
diclofenac diethylamine 2.32% w/w gel. 
 The current study investigated topical diclofenac diethylamine 2.32% w/w gel 
penetration into subdermal tissues and plasma. The primary objective was to determine 
whether diclofenac penetrates into the treated knee joint after repeated topical 
application. A post hoc analysis on the primary endpoint was done to determine whether 
diclofenac’s penetration of the knee joint was impacted by body mass index (BMI). The 
secondary objective was to evaluate relative exposure of diclofenac in the knee joint 
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versus plasma. Exploratory objectives were to evaluate treatment effects on 
cyclooxygenase-2 (COX-2) inhibition and inflammatory cytokines in the knee joint.  
 
METHODS 
Study Design and Procedures 
This phase 1, randomized, double-blind, placebo-controlled steady-state 
pharmacokinetic study (clinicaltrials.gov identifier NCT03497039) was conducted at 5 
European sites (4 in the UK, 1 in Germany) from July 19, 2018 through March 1, 2019. 
Participants were randomly assigned 2:1 to receive 4 g diclofenac diethylamine 2.32% 
w/w gel (92.8 mg diclofenac diethylamine, equivalent to 74.4 mg diclofenac, per 
application) or placebo gel, applied to the target knee twice daily at 12-hour intervals 
during the 7 days before scheduled knee arthroplasty for symptomatic end-stage OA 
(Figure 1). 
 There were four study-site assessment visits: a screening visit at study day −7, a 
baseline visit on study day 1 (7 days before surgery), a third assessment period lasting 
from hospital admittance the evening of day 7 through day 8 (day of surgery), and a 
final assessment before discharge, between days 8‒10.  
 A trained nurse or designee applied study medication using a standardized 
method either at the study site (first/last dose) or at the participant’s home or other 
convenient location (all intervening doses). Each 4 g dose was measured using a 
dosing card, applied to a 400 cm2 surface of the anterior aspect of the knee, centered 
over the knee joint line, that was first marked with a surgical site marking pen and 
stencil, and rubbed into the skin for about 1 minute. This dose represents the registered 
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posology for this approved product in the countries where the study sites were located. 
The final dose was administered approximately 12 (-1 to +3) hours before arthroplasty; 
if surgery was postponed, dosing continued for up to an additional week, after which the 
participant was withdrawn from the study if there were continued delays. 
 Paracetamol (maximum 4 g daily) was provided as rescue medication between 
screening and study day 7 to be used not only for knee pain but any pain (eg, 
headache) or fever. Codeine or tramadol could be prescribed at the investigator’s 
discretion if additional relief was needed.  
 During surgery, a tourniquet was used to provide a bloodless surgical field. 
Synovial fluid was collected by aspiration of the joint before arthrotomy and partitioned 
into 4 aliquots of 2.5‒3 mL. Two synovial tissue samples, approximately 2 to 3 cm3 each 
were obtained by sharp dissection. The synovium was resected from the supra-patellar 
pouch and from medial and lateral gutters; samples were not differentiated by specific 
site of collection. Samples were immediately frozen (−80°C) before being shipped to the 
lab for analysis. Diclofenac concentrations were measured in 2 aliquots each of synovial 
tissue, synovial fluid, and plasma.  
 Blood was drawn between anesthesia and surgery completion. Blood samples 
were also drawn within 1 hour before the first treatment dose at baseline, within 1 hour 
before the last treatment dose, and between the last dose and time of surgery.  
 Safety assessments included physical examinations and vital signs at all study 
visits; 12-lead electrocardiogram (ECG) and standard laboratory assessments at 
screening, before surgery, and at the final visit; and assessment of AEs at all study 




Randomization and Blinding 
Randomization was stratified by study center. Participants were assigned numbers via 
an interactive response technology system according to a schedule generated by the 
Statistics Department at the contract research organization (PPD). Participants, 
investigators, study site staff, the statistician, the sponsor, and any vendors who could 
influence study outcomes were blinded to treatment assignment. Active and placebo 
gels had identical odor, packaging, labeling, and administration schedule, and were as 
identical as possible in appearance. 
 
Selection of Study Population 
Men and women ≥50 years of age who had scheduled unilateral arthroplasty for 
treatment of OA with a radiographically confirmed Kellgren-Lawrence grade ≥2 within 
the past 6 months were eligible to participate. Participants had to have a BMI of 17.5 to 
<40 kg/m2 and total body weight >50 kg, had to be fit for surgery with no clinically 
relevant abnormalities, and had to be able and willing to comply with scheduled study 
procedures. Key exclusion criteria included damaged, open, or diseased skin around 
the knee, and acute or chronic medical or psychiatric condition or laboratory abnormality 
that could increase the participant’s risk, affect interpretation of study results, or 
interfere with drug absorption. 
 Participants could not use NSAIDs, COX-2 inhibitors, or dietary supplements 
within 7 days or 5 half-lives (whichever was longer) prior to the first dose of study 
medication and during the study (see washout period, Figure 1). Other prohibited 
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medications included intra-articular or periarticular procedures or injections in either 
knee within 3 months of study entry, systemic corticosteroids within 6 weeks, and any 
anticoagulants (warfarin, heparin, etc) within the preceding week or anti-aggregants 
(clopidogrel, ticagrelor, dipyridamole, abciximab, vorapaxar, etc) within the past month. 
Permitted exceptions included stable low doses of aspirin started ≥1 month before 
randomization and anticoagulant therapy for surgery. Any chondroprotectant or disease-
modifying OA drugs (eg, glucosamine or chondroitin sulfate) had to be stable for ≥1 
month prior to study entry and maintained throughout the study. 




The study protocol was reviewed and approved by an Ethics Committee in each country 
(Ethics Committee of the University of Würzburg, Versbacher Str. 9, Würzburg, 
Germany, D-97078; NHS Health Research Authority South Central - Hampshire A 
Research Ethics Committee, Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 
2NT, UK). The study was conducted in accordance with the International Council for 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use Good Clinical Practice guidelines and the principles outlined in the 
Declaration of Helsinki. Participants provided written informed consent prior to 





Primary pharmacokinetic endpoints consisted of diclofenac concentrations in synovial 
tissue and synovial fluid of the treated knee 12 hours after the last diclofenac application 
in the 7-day treatment period. Secondary pharmacokinetic endpoints included the ratio 
of diclofenac concentrations in the synovial tissue of the treated knee and plasma 
concentration and the ratio of diclofenac concentrations in the synovial fluid of the 
treated knee and plasma concentration at time of surgery. Exploratory 
pharmacodynamic (PD) endpoints included prostaglandin E2 (PGE2), interleukin-6 (IL-
6), and tumor necrosis factor alpha (TNFα) levels in synovial tissue and fluid of the 
treated knee. Safety outcomes consisted of incidence, severity, and relation to 
treatment of treatment-emergent AEs (TEAEs) and serious AEs; laboratory, vital sign, 
or ECG abnormalities; TEAEs leading to treatment or study discontinuation; and deaths. 
 
Bioanalytical Methodology 
A detailed description of the bioanalytical methodology is provided in the online 
supplemental material. 
 Diclofenac concentrations in synovial tissue, synovial fluid, and plasma were 
assayed by high-performance liquid chromatography tandem mass spectrometry, using 
diclofenac-d4 as the internal standard. The lower limit of quantitation was 0.23 ng/g in 
synovial tissue, 0.10 ng/mL in synovial fluid, 0.098 ng/mL in plasma. Across the range 
of quantitation, the percent coefficient of variation (%CV) ranged from 0.1% to 2.9% in 
synovial tissue, 0.9% to 5.5% in synovial fluid, and 0.9% to 2.9% in plasma; the percent 
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bias was −0.9% to 1%, −1.7% to 3.0%, and −9.3% to 4.8% in synovial tissue, synovial 
fluid, and plasma, respectively. 
 PGE2 concentrations in synovial tissue and fluid were measured using an 
enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification was 2.62 
ng/mL in synovial tissue and 0.013 ng/mL in synovial fluid. Percent relative error (%RE) 
for PGE2 detection was −3.2% to 3.2%; %CV was 2.9% to 11.2%.  
 IL-6 and TNFα were measured with an electrochemiluminescence assay with a 
Meso Scale Discovery (MSD) Sector Imager 6000 electrochemiluminescence reader. 
Diluted samples were analyzed using a V-PLEX human cytokine multiplex 
proinflammatory panel (excluding proinflammatory markers other than IL-6 and TNFα). 
Analysis was done using MSD’s Discovery Workbench version V4.0.12.1 software. The 
range of quantification was 3.16‒976.00 pg/mL for IL-6 and 1.38 to 496.00 pg/mL for 
TNFα in both synovial tissue and fluid. Intra-assay accuracy (%bias) and precision 
(%CV) for IL-6 and TNFα were both 20% (25% upper and lower limit of quantification). 
 
Statistical Analyses 
No formal estimation of sample size was conducted. Enrollment of 50 participants was 
planned to ensure evaluable data from at least 45 (30 assigned to active treatment and 
15 to placebo), which was considered adequate to characterize diclofenac levels in 
synovial tissue and synovial fluid based on similar studies of oral or topical NSAIDs or 
joint inflammation.17-22 No power calculations were made for exploratory PD endpoints. 
 The safety population comprised all participants who were randomized and 
received at least one dose of study treatment. The analysis population comprised those 
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from the safety population who completed surgery and had evaluable synovial tissue or 
fluid samples. 
 Diclofenac concentrations in synovial tissue and fluid were summarized 
descriptively. Geometric means with their two-sided 95% confidence interval (CI) were 
calculated, assuming data on the log scale were normally distributed (subsequently 
confirmed on the data using q-q plots). Geometric means provide a robust summary 
measure accounting for the specific nature of concentration data, which are bounded by 
zero and positively skewed, as illustrated by a median lower than the arithmetic mean. 
While no formal hypothesis testing was performed, the criterion for success was that 
diclofenac would be detectable within synovial tissue or fluid. Post hoc analyses were 
performed to calculate Spearman’s rank correlation coefficient (r) between BMI and 
diclofenac concentration in synovial tissue and synovial fluid. 
 The same statistical approach as for the primary outcomes was used to 
summarize the ratios between diclofenac concentrations in synovial tissue or fluid and 
plasma and the concentrations of PGE2, IL-6, and TNFα. For each exploratory endpoint, 
a two-sided t-test at an alpha level of 0.05 was conducted to compare the log-
transformed mean levels. The geometric mean ratio between the treatment groups was 
calculated as a measure of the contrast between the groups, also known as the effect 
size. The geometric mean ratio gives an estimate of the relative effect of diclofenac 
versus placebo on the corresponding PD biomarker. The associated 95% CI was 
calculated to give a range of plausible values (ie, compatible with the observed data) for 
this effect. 





Subject Disposition, Baseline Characteristics, and Compliance 
Forty-seven participants were enrolled: 30 in the diclofenac group and 17 in the placebo 
group. Forty-five (95.7%; diclofenac n=29; placebo n=16) completed the study and had 
evaluable synovial tissue or fluid (Figure 2). Surgery was postponed past day 7 in 5/45 
participants (2 diclofenac, 3 placebo). Average number of days from baseline to surgery 
was 7.27 (SD 1.01). All participants had protocol deviations (Supplemental Table S2), 
which most commonly concerned collection and handling of samples and storage of 
study treatment. The bioanalytical laboratory determined that none of these protocol 
deviations prevented proper analysis of the samples. 
 Mean (SD) age was 71.2 (7.9) years, 52.2% were women, and mean (SD) BMI 
was 30.7 (4.8) kg/m2 (Table 1). All subjects had 100% of scheduled treatment 
applications, and mean exposure was 59.17 g of gel in the diclofenac group and 61.3 g 
in the placebo group. Rescue medication (paracetamol) was used by 79.3% of the 
diclofenac group and 75.0% of the placebo group; median (range) number of 500-mg 
tablets used was 8 (1–54) and 13 (6–42) respectively. In addition, 16.7% of the 
diclofenac group and 17.6% of the placebo group used NSAIDs or corticosteroids 
between screening and collection of synovial samples, although these medications were 




Synovial Tissue and Fluid Concentrations 
All participants treated with topical diclofenac had measurable concentrations of 
diclofenac in synovial tissue and synovial fluid at 12‒15 hours after the last application 
(Figure 3). Geometric mean (95% CI) diclofenac concentrations were 1.57 (1.12, 2.20) 
ng/g in synovial tissue and 2.27 (1.87, 2.76) ng/mL in synovial fluid (Table 2), which 
were well above the limits of detection for the assay (0.23 ng/g and 0.10 ng/mL, 
respectively). Diclofenac concentrations ranged from 0.29 to 9.27 ng/g in synovial tissue 
and 0.65 to 6.74 ng/mL in synovial fluid. Thus, although there was a degree of variability 
in individual synovial tissue and fluid concentrations, diclofenac penetrated into the 
affected joint in all participants. No correlation (r=−0.003) between BMI and synovial 
fluid diclofenac concentration, and weak positive correlation (r=0.315) between BMI and 
synovial tissue diclofenac concentration were observed. These results suggest that BMI 
has no impact on diclofenac’s penetration into the knee.  
 
Ratio of Synovial Tissue and Fluid Concentrations to Plasma Concentrations 
Plasma concentrations are reported descriptively in Table 2. The geometric mean (95% 
CI) ratio of diclofenac concentration in synovial tissue:plasma was 0.32 (0.23, 0.45) and 
the ratio of synovial fluid:plasma was 0.46 (0.40, 0.54), indicating greater diclofenac 





Exploratory Endpoints: Inflammatory Markers 
Concentrations of PGE2, IL-6, and TNFα in synovial tissue and fluid at about 12 hours 
after the last dose are presented in Supplemental Table S3. Results of this exploratory 
analysis were inconclusive. TNFα and IL-6 could not be quantified in synovial tissue, 
and TNFα was quantifiable in synovial fluid in <35% of the diclofenac group and 25% of 
the placebo group. Even for parameters that were satisfactorily quantified (PGE2 in 
synovial tissue and fluid and IL-6 in synovial fluid), the observed variability was too large 
to draw conclusions regarding diclofenac’s effect. The 95% CIs for the geometric mean 
ratios (which give a range of plausible values for the relative effect of diclofenac versus 
placebo on the corresponding biomarkers) were wide. 
 
Safety 
Overall, 16 (55.2%) participants treated with topical diclofenac and 10 (58.8%) in the 
placebo group experienced TEAEs, most commonly nausea (17.2% vs 11.8%), and 
vomiting (13.8% vs 5.9%, all in the postoperative setting), and falls (10.3% vs 0) (Table 
4). No TEAEs were considered by the investigator to be related to treatment. 
 One participant in the diclofenac group experienced 2 serious TEAEs consisting 
of moderate grade 2 Escherichia urinary tract infection and moderate grade 2 
hypotension. The only severe TEAE was a postprocedural complication (vasovagal 
syncope on first mobilization, not considered diclofenac related) in a participant who had 
received diclofenac. There were no deaths; no TEAEs leading to study drug or study 
discontinuation, or dose reduction or interruption; and no clinically notable changes in 





Local concentrations of NSAIDs in the joint are thought to be important to their 
therapeutic effect in management of OA-related pain because inflammation in the joint 
is a key component of the pathogenesis, and synovitis in particular is associated with 
joint pain.17,23-26 Like all NSAIDs, diclofenac relieves pain by preferentially blocking 
COX-2, thereby inhibiting production of proinflammatory PGE2
27-29 and limiting 
prostaglandin-induced inflammation and pain.28,30 The study met its primary objective of 
demonstrating that diclofenac diethylamine 2.32% w/w gel penetrates into underlying 
target tissues after repeated topical application to the knee in patients with OA. 
Diclofenac was detected in the synovial tissue and synovial fluid at 12‒15 hours after 
the last application in all subjects treated with diclofenac diethylamine 2.32% w/w gel for 
7 days. Thus, local exposure at the site of action persisted through the 12-hour dosing 
interval, supporting the current twice-daily dosing posology. 
 Mean BMI in the diclofenac group was 31.2 kg/m2. The high prevalence of 
obesity in our study participants is not unexpected because obesity is a risk factor for 
knee OA.31 In all participants, diclofenac was detectable after 12 hours, including in 
those who were overweight or obese and presumably had a thicker fatty tissue layer to 
penetrate compared with normal weight individuals. In the post hoc analysis, no 
correlation between BMI and synovial fluid diclofenac concentration, and a weak 
positive correlation between BMI and synovial tissue diclofenac concentration were 
observed. Taken together, these results suggest that BMI does not impact diclofenac 
penetration into the knee. The mechanisms by which highly protein-bound topical 
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agents such as diclofenac penetrate into deep tissue largely involve convective blood, 
lymphatic, and interstitial flow.32 These mechanisms likely apply to adipose tissue as 
well, because adipose tissue is highly vascularized,33 which may explain the lack of a 
negative correlation between BMI and diclofenac penetration.  
 Our overall findings on the primary endpoint support those of previous studies 
showing that topical diclofenac permeates underlying tissues, and enters the 
synovium.22,34-36 For example, in patients undergoing arthroplasty for knee joint 
effusions, after 3 days of topical diclofenac sodium 4% spray gel (80 or 120 mg/d) 
application, the median (range) diclofenac concentration in synovial tissue was 36.2 
(1.2‒1232.0) ng/g with the 80 mg dose and 42.8 (0.8‒594.0) ng/g with 120 mg. The 
median (range) concentration in synovial fluid was 2.6 (0.4‒408.5) ng/mL and 2.8 (0.2‒
47.1) ng/mL respectively, and in plasma was 3.9 (1.3‒302.2) ng/mL and 4.1 (1.1‒23.0) 
ng/mL).22 In patients undergoing arthroplasty for knee OA, a single dose of diclofenac 
sodium tape (15 mg) applied in two strips to the medial and lateral aspects of the knee 
12 hours before surgery resulted in mean (SD) diclofenac concentrations of 4.99 (3.84) 
ng/mL in synovial membrane, 1.96 (0.68) ng/mL in synovial fluid, and 4.70 (1.95) ng/mL 
in plasma.35 In another study, 23 patients scheduled for knee arthroplasty for OA (91%), 
trauma (4.5%), or polyarthritis (4.5%) were treated with 80 mg diclofenac 
diethylammonium emulsion gel 3 times daily for 2‒5 days through the morning of 
surgery, applied medially and laterally (40 mg each) to either the presurgical or 
contralateral knee.36 When the gel was applied to the affected knee, mean (range) 
diclofenac concentrations were 25.4 (5.7‒81.2) ng/mg in the synovial membrane, 19.2 
(4.5‒87.1) ng/mL in the synovia, and 18.0 (4.8‒44.9) ng/mL in the plasma.36 Variability 
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in diclofenac concentrations across studies may relate to differences in study 
parameters such as dosing regimens, dosing frequency, sampling time, administration 
site, diclofenac formulation, thickness of participants’ stratum corneum layer, and body 
mass and constitution. 
 Geometric means and their 95% CIs of diclofenac concentration in synovial 
tissue:plasma and synovial fluid:plasma ratios were all below 1, indicating greater 
concentrations in plasma than in the joint at ≥12 hours after the final dose. This differs 
from prior studies of topical diclofenac described above, which typically showed plasma 
levels that were lower than synovial tissue levels and higher than or similar to synovial 
fluid levels.22,35,36   
 Speculating on potential reasons why our results do not conform to this pattern, 
one may suspect inferior and/or slower direct penetration to the joint. However, it is also 
conceivable that tissue penetration is particularly fast, along with facilitated systemic 
redistribution and low retention within the joint. The latter scenario would suggest that 
diclofenac diethylamine 2.32% w/w gel might be a rapidly effective topical formulation, 
and the maximum concentration in synovial tissue and fluid along with a high 
fluid/tissue-to-plasma ratio occur early during the anticipated 12-hour duration of action. 
Accordingly, our results would confirm that even after the end of the 12-hour dosing 
interval, significant concentrations of the active compound are still detectable in the 
synovial fluid and tissue.   
 This hypothesis of sufficient tissue penetration to yield an appropriate analgesic 
effect across the 12-hour dosing interval is supported by the finding that a smaller 
proportion of participants in the diclofenac group required paracetamol rescue 
18 
 
medication compared with the placebo group, even though the minimum effective 
diclofenac concentrations in synovial tissue, synovial fluid, and plasma are still being 
defined. Furthermore, topical diclofenac has established efficacy in a variety of 
conditions including OA.1-3,37-41 
 IL-1β and TNFα are predominant proinflammatory cytokines that regulate 
production of various other proinflammatory cytokines, such as IL-6 and IL-8.42-44 
Inflammatory cytokines downstream of PGE2 in the signal transduction pathway (eg, 
TNFα, IL-6) are reduced when PGE2 production is inhibited by NSAIDs.
29,45 Therefore, 
this study sought to characterize these inflammatory biomarkers to further explore 
whether they were reduced in the presence of diclofenac in the joint. It is important to 
note that the study was not statistically powered to detect a difference between 
treatment groups for these PD biomarkers, as they were exploratory endpoints. At the 
time of study design, no in vivo data were available on the effect of diclofenac on these 
markers. As such, the potential size of the effect, the variability of the data, and the 
probability of detecting a difference between the groups were unknown. In the end, the 
precision around the estimates derived in the study was poor, which can be put into 
perspective with several considerations. First, the variability of the PD biomarkers data 
was found to be high compared with the relatively small number of participants included 
in the study. Secondly, PD markers were only measured once, during surgery, and not 
at baseline, which avoided the burden of an additional invasive procedure but did not 
allow for within-subject comparisons, which would have reduced variability. Finally, a 
2:1 randomization ratio was chosen to put emphasis on the primary and secondary 
objectives by enrolling more subjects in the diclofenac arm, but was suboptimal for 
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exploratory comparisons; a 1:1 randomization ratio would have increased the precision 
around the observed effect size.  
 Levels of PGE2, IL-6, and TNFα in synovial tissue and fluid of patients with OA 
are highly variable,17,46,47 and published data regarding the minimal effective therapeutic 
concentrations of diclofenac in target tissues as assessed by the diclofenac IC50 (ie, the 
concentration that produces 50% of the maximum inhibition of prostaglandin synthesis) 
for PGE2 are inconsistent.
15 Accordingly the minimum concentration of diclofenac in 
synovial tissue and fluid required to produce meaningful reductions in these biomarkers 
remains to be characterized. Even though synovial tissue and fluid concentrations 
attained in this study may appear comparatively low, we cannot draw any conclusions 
as to whether these were sufficient to yield a clinically meaningful effect in terms of pain 
reduction.  
 Our results were in line with those of Rosengren et al48 who found no detectable 
TNFα in synovial tissue from 15 patients undergoing hip or knee replacement for OA. 
The low or undetectable levels of TNFα and IL-6 may be due to limited inflammatory 
activity in the knee joints of our participants, resulting from limited loading of the joint in 
advance of surgery or long-standing, advanced-stage OA (which is associated with less 
inflammation compared with early-stage OA17). Low/undetectable levels of inflammatory 
markers even in the placebo group confirm minimal inflammatory activity in these joints, 
limiting the potential for further reductions in those parameters. Research is ongoing to 
determine what other mediators of local pain and inflammation may play a role in 
patient-experienced discomfort; it is unknown to what extent those mediators are 
affected when exposed to diclofenac in the joint.  
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 Topical diclofenac diethylamine 2.32% w/w gel had an overall rate of TEAEs 
similar to that of placebo, and there were no treatment-related TEAEs. It has been 
reported that AEs with topical diclofenac are largely local application-site reactions13,49 
with fewer systemic effects, especially gastrointestinal events and liver enzyme 
elevations, compared with oral NSAIDs.49 Here, although the incidence of 
gastrointestinal TEAEs was numerically higher in the diclofenac arm than in the placebo 
arm, none were considered treatment related. Local reactions at the application site 
were not more common with diclofenac than placebo. 
 This study has a number of strengths and limitations. Concentrations of 
diclofenac and inflammatory biomarkers were objectively measured using validated 
procedures. This study used a newer assay with an improved ability to detect low 
concentrations of diclofenac (lower limit of quantitation: 0.233 ng/g in synovial tissue, 
0.100 ng/mL in synovial fluid, and 0.0977 ng/mL in plasma) compared with previous 
studies (synovial tissue: 0.24 to 1.5 ng/g; synovial fluid: ≤0.15‒8 ng/mL; plasma: ≤0.15‒
8 ng/mL).22,35,36 Treatment was applied by a trained nurse or designee using a 
standardized procedure to ensure consistent dosing and compliance. One limitation is 
that the synovial tissue and fluid were collected only at 12 hours after last dose (the end 
of the dosing cycle), after 7 days of diclofenac application. Thus, diclofenac 
concentrations and cytokine levels earlier in the dosing cycle were not assessed. In 
addition, the study population consisted of those undergoing knee arthroplasty for OA 
and is not necessarily generalizable to those with earlier-stage OA. This phase 2 study 
was designed to assess pharmacokinetics only and did not include efficacy outcomes; 
accordingly, evaluating the relationship between diclofenac concentrations in the joint 
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Topical diclofenac diethylamine 2.32% w/w gel 4 g applied twice daily for 7 days was 
absorbed by the skin and successfully penetrated into the joint, with detectable levels 
found in both synovial tissue and fluid at the end of the final 12-hour dosing interval. 
Additional studies are needed to identify the minimum concentration in synovial tissue, 
synovial fluid, and/or plasma needed to obtain pain relief, and to clarify the effects of 
topical diclofenac on inflammatory biomarkers. Topical diclofenac diethylamine 2.32% 
w/w gel had a similar incidence of TEAEs compared with placebo and no TEAEs were 
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Table 1. Demographics, Safety Population  
 Diclofenac Diethylamine 
2.32% w/w Gel (N=29) 
Placebo Gel (N=17) 
Age, mean (SD), years 70.9 (7.6) 71.7 (8.6) 
Sex, n (%)   
Female 15 (51.7) 9 (52.9) 
Male 14 (48.3) 8 (47.1) 
Height, mean (SD), cm 168.0 (7.8) 166.3 (8.9) 
Weight, mean (SD), kg 88.0 (15.9) 82.8 (10.8) 
BMI, mean (SD), kg/m2 31.2 (5.3) 30.0 (4.0) 






Table 2. Diclofenac Concentrations in Synovial Tissue, Synovial Fluid, and 
Plasma 12 Hours After Last Administration of Topical Diclofenac Diethylamine 
2.32% w/w Gel 4 g BID for 7 Days (N=29), Analysis Population 









Median 1.73 2.12 4.76 
Range 0.29‒9.27 0.65‒6.74 0.92‒16.72 
Geometric meanb  1.57 2.27 ND 
95% CI 1.12, 2.20 1.87, 2.76 ND 
aPrimary endpoint. 
bThe geometric mean (95% CI) is calculated by back-transforming the mean (95% CI) of the log-
transformed data. 




Table 3. Ratios of Diclofenac Concentration in Synovial Tissue:Plasma and 
Synovial Fluid:Plasma 12 Hours After Last Administration of Topical Diclofenac 
Diethylamine 2.32% w/w Gel 4 g BID for 7 Days (Diclofenac Group, N=29), 
Analysis Population 
 Ratio of Synovial Tissue 
Concentration to Plasma 
Concentration, (ng/g)/(ng/mL) 
Ratio of Synovial Fluid 
Concentration to Plasma 
Concentration, (ng/mL)/(ng/mL)
Median  0.242 0.448 
Range 0.10‒10.04 0.20‒2.19 
Geometric meana  0.320 0.463 
95% CI 0.228, 0.450 0.397, 0.539 
aThe geometric mean (95% CI) is calculated by back-transforming the mean (95% CI) of the log-
transformed data. 
BID, twice daily; CI, confidence interval. 
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Table 4. Summary of Safety Outcomes, Safety Population 




2.32% w/w Gel 
(N=29), n (%) 
Placebo Gel 
(N=17), n (%) 
Any AE 18 (62.1) 11 (64.7) 
Any TEAE 16 (55.2) 10 (58.8) 
Serious TEAEs 1 (3.4) 0 
Treatment-related TEAEs 0 0 
TEAEs leading to treatment discontinuation 0 0 
TEAEs leading to study discontinuation 0 0 
Deaths 0 0 
TEAEs occurring in ≥2 participants in either arm   
Nausea 5 (17.2) 2 (11.8) 
Vomiting 4 (13.8) 1 (5.9) 
Fall 3 (10.3) 0 
Bursal fluid accumulation 2 (6.9) 1 (5.9) 
C-reactive protein increased 2 (6.9) 1 (5.9) 




Figure 1. Study design 
  










Figure 3. Diclofenac concentration in synovial tissue and synovial fluid 12 









Blood samples were centrifuged at 1500 G at 4°C for 10 minutes, and the isolated 
plasma was frozen and shipped to the bioanalytical laboratory. Synovial tissue and fluid 
samples were retrieved during surgery, frozen immediately, and shipped to the 
bioanalytical laboratory. Bioanalysis was performed by FARMOVS (Pty) Ltd 
(Bloemfontein, South Africa) for analysis of diclofenac concentrations in synovial tissue, 
synovial fluid, and plasma, and by Synexa Life Sciences, Ltd (Cape Town, South Africa) 
for prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα) 
levels in synovial tissue and fluid. 
 For analysis of diclofenac concentrations, synovial tissue samples were 
pulverized and ground to a fine powder in liquid nitrogen. The powdered samples were 
transferred to microfuge tubes with methanol and metal balls, vortexed and 
homogenized twice using a Bead Blaster™ 24 (Benchmark Scientific, Sayreville, NJ), 
and centrifuged. The supernatants were stored at −70°C until sample preparation.  
 Diclofenac concentrations in synovial tissue, synovial fluid, and plasma were 
assayed by high-performance liquid chromatography tandem mass spectrometry, using 
diclofenac-d4 as the internal standard. Liquid-liquid extraction was performed with a 
mixture of hexane and dichloromethane as the extraction solvent for synovial tissue and 
fluid samples, and hexane and ethyl acetate for plasma samples. The extracts were 
dried under nitrogen and reconstituted in a solution mixture of acetonitrile and 
ammonium acetate. The sample extracts were injected into a chromatography system 
equipped with an autosampler and an Agilent Zorbax Eclipse XDB-C18 (150 x 4.6 mm) 
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5 µm analytical column. The autosampler was fitted with a cooling device to keep the 
samples at ~5°C. Mobile phase (acetonitrile and ammonium acetate) was delivered 
isocratically. Multiple reaction monitoring was done with a Sciex API5500 mass 
spectrometer (Sciex, Framingham, MA) , with electrospray ionization in negative mode. 
Mass-to-charge ratios (m/z) in unit resolution was set at 293.9 ± 0.1 for diclofenac 
deprotonated precursor ion and 249.8 ± 0.1 for product ion were used; m/z for the 
internal standard diclofenac-d4 was 299.5 ± 0.6 and 255.5 ± 0.6 for deprotonated 
precursor and product ions, respectively.  
 Data collection and analysis were performed using Analyst® version 1.6.2 (Sciex) 
and Watson LIMS™ version 7.4.2 software (ThermoFisher Scientific, Waltham, MA). The 
lower limit of quantitation was 0.23 ng/g in synovial tissue, 0.10 ng/mL in synovial fluid, 
and 0.098 ng/mL in plasma. Over 3 consecutive validation runs, between-run accuracy 
had to be within 15% over the range (and within 20% at the lower limit of quantitation), 
and between-run precision had to be ≤15% (20% at the lower limit of quantitation). 
Across the range of quantitation, the percent coefficient of variation (%CV) ranged from 
0.1% to 2.9% in synovial tissue, 0.9% to 5.5% in synovial fluid, and 0.9% to 2.9% in 
plasma; the percent bias was −0.9% to 1%, −1.7% to 3.0%, and −9.3% to 4.8% in 
synovial tissue, synovial fluid, and plasma, respectively. 
 PGE2 concentrations in synovial tissue and fluid were measured using an 
enzyme-linked immunosorbent assay (ELISA). Following dilution, samples were 
analyzed using a PGE2 multiformat enzyme immunoassay kit (DetectX
®; Arbor Assays, 
Ann Arbor, MI) and BioTek® Gen5 version 1.11.5 software (BioTek, Winooski, VT). The 
lower limit of quantification was 2.62 ng/mL in synovial tissue and 0.013 ng/mL in 
37 
 
synovial fluid. Percent relative error (%RE) for PGE2 detection was −3.2% to 3.2%; %CV 
was 2.9% to 11.2%.  
 IL-6 and TNFα were measured with an electrochemiluminescence assay with a 
Meso Scale Discovery (MSD) Sector Imager 6000 electrochemiluminescence reader 
(Meso Scale Diagnostics, Rockville, MD). Following dilution, samples were analyzed 
using a V-PLEX human cytokine multiplex proinflammatory panel (excluding 
proinflammatory markers other than IL-6 and TNFα). Microplate wells were coated with 
antibodies against IL-6 and TNFα before the samples were added; bound analytes (IL-6 
and TNFα) were then detected with SULFO-Tag conjugated antibodies. MSD Read 
buffer was added, and electricity was applied to plate electrodes via the MSD Sector 
Imager leading to light emission. Analysis was done using MSD’s Discovery Workbench 
version V4.0.12.1 software. The range of quantification was 3.16‒976.00 pg/mL for IL-6 
and 1.38 to 496.00 pg/mL for TNFα in both synovial tissue and fluid. Intra-assay 
accuracy (%bias) and precision (%CV) for IL-6 and TNFα were both 20% (25% upper 





Supplemental Table S1. Complete Inclusion and Exclusion Criteria 
Inclusion Criteria  Written informed consent provided 
 Men and women ≥50 years of age at screening 
 Diagnosis of knee OA with radiographic evidence within the last 
6 months confirming Kellgren-Lawrence Grade ≥2 and 
scheduled unilateral knee arthroplasty  
 Good general physical health and deemed fit for surgery by the 
investigator, with no clinically relevant abnormalities identified by 
medical history, physical exam including vital signs, 12-lead 
ECG, and laboratory testing 
 Body mass index 17.5 to <40 kg/m2 and total body weight >50 
kg  
 Willingness to comply with scheduled visits, treatment plan, 
laboratory testing, and other study procedures 
 Women of childbearing potential and at risk for pregnancy had 
to agree to use highly effective contraception throughout the 
study for ≥21 days after the last dose of study treatment 
Exclusion Criteria  Study site personnel involved in the study conduct and their 
family members, study site staff otherwise supervised by the 
investigator, or employees of the Sponsor who were directly 
involved with the study 
 Participation in a study involving an investigational drug within 1 
month prior to entry or during study participation 
 Acute or chronic medical or psychiatric condition or laboratory 
abnormality that could increase the risk associated with the 
study or the investigational product or interfere with 
interpretation of the study results 
 Pregnancy or breastfeeding 
 Known or suspected intolerance or hypersensitivity to the study 
materials or their ingredients 
 History of asthma, angioedema, urticaria, or acute rhinitis 
precipitated by acetylsalicylic acid or other NSAIDs 
 Broken or diseased skin, skin wound, or other open injury 
around the knee 
 Inability or unwillingness to comply with lifestyle guidelines or 
investigator instructions 
 Positive urine drug screen during screening (day −7) 
 Any condition possibly affecting drug absorption (eg, 
gastrectomy) 
 History of regular alcohol consumption >14 drinks/week within 6 
months of screening 
 Previous enrollment in this study 





 Prescription or nonprescription drugs (unless deemed 
necessary by investigator), NSAIDs, COX-2 inhibitors, or dietary 
supplements within 7 days or 5 half-lives (whichever was longer) 
prior to first dose of study treatment and during the study.  
o Participants had to be willing to avoid use of topical or 
systemic analgesics or anti-inflammatory treatments 
other than study medication and rescue medication(s) 
during the washout period and treatment period 
 Any intra-articular or peri-articular procedures or injections in 
either knee within the previous 3 months 
 Any systemic treatment with corticosteroids within the previous 
6 weeks (topical corticosteroids applied to sites other than the 
knees were permitted up to screening visit only) 
 Any chondroprotectant or disease-modifying OA drugs (eg, 
glucosamine or chondroitin sulfate) unless dose was stable over 
the month prior to screening and would be maintained 
throughout the study 
 Any systemic anti-inflammatory or analgesic drugs at screening 
if 5 times their elimination half-life exceeded 7 days (ie, half-life 
was >33.6 hours) 
 Anticoagulants (eg, warfarin, heparin) in the week prior to 
screening or anti-aggregants within the month prior to screening 
with the exception of anticoagulant therapy for surgery and 
aspirin at stable low doses started at least 1 month before 
randomization and maintained at a stable dose throughout the 
study  
 Any other investigational drugs within the month prior to 
screening or 5 half-lives before the first dose of study 









2.32% w/w Gel 
(N=30), n (%) 
Placebo Gel 
(N=17), n (%) 
Any significant protocol deviations 30 (100) 17 (100) 
Inadequate/inappropriate collection, handling, 
processing, or storing of study samples 
26 (86.7) 13 (76.5) 
Incorrect storage of study treatment 12 (40.0) 6 (35.3) 
Inadequate execution, completion, or 
documentation of informed consenta 
11 (36.7) 6 (35.3) 
Study procedure performed by staff member not 
appropriately delegated 
9 (30.0) 5 (29.4) 
NSAIDs and corticosteroids administered between 
screening and collection of synovial samples 
5 (16.7) 3 (17.6) 
Failure to maintain subject’s confidentiality 
information 
3 (10.0) 0 
Exclusion criteria met, but participant was still 
enrolled and provided samples 
3 (10.0) 0 
One or more investigational product doses was 
missed, including incorrect administration 
1 (3.3) 2 (11.8) 
Rescue medical misuse 1 (3.3) 0 
Participant was incorrectly randomized 1 (3.3) 0 
aA majority of the consent-related protocol deviations (9/11 in the diclofenac group and 5/6 in the placebo 
group) were the result of informed consent being executed by a site staff member who was not 




Supplemental Table S3. PGE2, IL-6, and TNFα Levels in Synovial Tissue and Fluid, 
Analysis Population 
aLevels below the limit of quantification (LOQ) were replaced by LOQ/2. PGE2 LOQ = 2.62 ng/mL in 
synovial tissue and 0.013 ng/mL in synovial fluid. IL-6 LOQ = 3.16 pg/mL in both synovial tissue and fluid. 
TNFα LOQ = 1.38 pg/mL in synovial tissue and fluid. However, for 5 participants (diclofenac n=3; placebo 
n=2) with synovial tissue levels of PGE2 <LOQ, the laboratory was able to quantify PGE2 using altered 
dilution factors, so these quantified values were used rather than LOQ/2. In addition, 1 participant in the 
















PGE2, ng/mL     
Number (%) with quantifiable 
levela 
28 (96.6%) 16 (100%) 29 (100%) 16 (100%) 
Median 36.74 46.25 0.08 0.08 
Range 1.3‒576.4 2.3‒273.7 0.02‒3.20 0.04‒1.24 
Geometric meanb 32.35 28.26 0.09 0.13 
95% CI 16.37, 63.92 11.30, 70.69 0.062, 0.135 0.076, 0.219 
Ratio of LS Means (95% CI) 
P valuec 
1.14 (0.37‒3.59) P=0.8123 0.71 (0.37‒1.37) P=0.2945 
IL-6, pg/mL     
Number (%) with quantifiable 
levela 
1 (3.4%) 0 24 (82.8%) 16 (100%) 
Median NC NC 11.23 15.43 
Range NC NC 1.58‒884.82 5.48‒472.62 
Geometric meanb NC NC 13.99 24.28 
95% CI NC NC 7.95, 24.62 11.35, 51.97 
Ratio of LS Means (95% CI) 
P valuec 
NC 0.58 (0.22‒1.49) P=0.2473 
TNFα, pg/mL     
Number (%) with quantifiable 
levela 
0 0 10 (34.5%) 4 (25.0%) 
Median NC NC 0.69 0.69 
Range NC NC 0.69‒5.38 0.69‒1.91 
Geometric meanb NC NC 1.00 0.87 
95% CI NC NC 0.82, 1.21 0.67, 1.13 
Ratio of LS Means (95% CI) 
P valuec 
NC 1.15 (0.83‒1.58) P=0.3986 
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diclofenac group had PGE2 >LOQ in synovial fluid but the value was not quantifiable due to insufficient 
volume for dilution; this patient’s PGE2 concentration was set to the upper LOQ (3.20 ng/mL). 
bBased on t-test using log transformed data; results are back transformed into original scale for the 
geometric mean and its 95% CI. 
cDifference between diclofenac and placebo concentrations based on t-test; P values are two sided using 
0.05 level of significance. 
CI, confidence interval; IL-6, interleukin-6; LS, least squares; NC, not calculable; PGE2, prostaglandin E2; 
TNFα, tumor necrosis factor alpha. 
 
